Loading...
•
Mar 31, 2022
Abbott Q1 2022 Earnings Report
Abbott's diversified business performed well in a challenging environment, with strong performance in Medical Devices and Established Pharmaceuticals.
Key Takeaways
Abbott's Q1 2022 sales reached $11.9 billion, a 13.8% increase, or 17.5% on an organic basis. Excluding COVID-19 testing-related sales, worldwide sales increased 3.9 percent on a reported basis and 7.7 percent on an organic basis. The company projects full-year 2022 diluted earnings per share under GAAP of at least $3.35 and adjusted diluted earnings per share of at least $4.70.
Worldwide sales increased 13.8 percent on a reported basis and 17.5 percent on an organic basis.
Worldwide sales, excluding COVID-19 testing-related sales, increased 3.9 percent on a reported basis and 7.7 percent on an organic basis.
Established Pharmaceuticals sales increased 7.1 percent on a reported basis and 13.4 percent on an organic basis.
Worldwide Medical Devices sales increased 7.4 percent on a reported basis and 11.5 percent on an organic basis.
Forward Guidance
Abbott projects full-year 2022 diluted earnings per share under GAAP of at least $3.35. Excluding specified items, projected adjusted diluted earnings per share of at least $4.70 remains unchanged for the full-year 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...